Merck & Co., Inc. (MRK)

Merck’s Q3 results showed 5% sales growth to $18.1 billion, supported by Keytruda, Winrevair, and animal health. The main investment debate remains whether new products, acquisitions, and pipeline programs can offset Keytruda’s expected U.S. patent pressure beginning in 2028. As of November 9, MRK was up 1.85% in pre-market trading against the prior close; the regular session had not opened.